49 recruiting, 33 completed, 22 not yet recruiting, 13 unknown. 138 Phase 2, 17 Phase 1.
Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2027-02-01 | 2026-10-23 |
| Psilocybin for Methamphetamine Use Disorder Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions). - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Peter Hendricks | 42 | 2027-02-01 | 2026-09-21 |
| Psilocybin FCR Early-Stage Breast Cancer Psilocybin 25 mg, Psilocybin 5 mg - Early-stage Breast Cancer, Fear of Cancer Recurrence | Phase 2 | Not yet recruiting | NYU Langone Health | 100 | 2027-01-02 | 2026-11-02 |
| Psilocybin for Depression in Veterans Psilocybin, modafinil, zolpidem - Major Depression | Phase 2 | Not yet recruiting | VA Office of Research and Development | 150 | 2027-01-01 | 2026-10-26 |
| Group PACBT for Depression Psilocybin (drug), Group Cognitive Behavioral Therapy - Depression - Major Depressive Disorder, Psilocybin | Phase 2 | Not yet recruiting | University of California, Los Angeles | 30 | 2027-01-01 | 2026-05-04 |
| Effects of Psilocybin on Craving in Nicotine Dependence Psilocybin (drug) - Nicotine Dependence | Phase 2 | Not yet recruiting | University of British Columbia | 3 | 2027-01-01 | 2026-10-01 |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | University of New Mexico | 150 | 2026-12-31 | 2026-10-30 |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg - Chronic Low Back Pain (CLBP), Physical Therapy | Phase 2 | Not yet recruiting | Yale University | 48 | 2026-12-01 | 2026-10-26 |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder Psilocybin - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 36 | 2026-11-15 | 2026-10-09 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-05 | 2026-11-02 |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy Psilocybin (drug), Standard of Care (SOC) - Psilocybin, Neuropathy | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 83 | 2026-11-04 | 2026-10-05 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Not yet recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-11-01 | 2026-08-11 |
| MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial PEX010 25 mg psilocybin, PEX010 5 mg psilocybin, Standard Psilocybin-Assisted Therapy - Advanced Cancer, Demoralization | Phase 2 | Not yet recruiting | University of Calgary | 60 | 2026-10-30 | 2026-09-02 |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment Psilocybin, Pimavanserin, Inactive Placebo - Mood (Psychological Function), Well Being | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 20 | 2026-10-29 | 2026-11-02 |
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate), Psychotherapy assisted by low-dose psilocybin (1 mg) - Gambling Disorder | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2026-10-08 | 2026-10-16 |
| Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence Psilocybin - Post Traumatic Stress Disorder PTSD, Intimate Partner Violence (IPV) | Phase 2 | Not yet recruiting | University of Calgary | 76 | 2026-10-01 | 2026-09-08 |
| Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-09-15 | 2026-08-12 |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial Psilocybin (high dose), Psilocybin (low dose), PEARL Therapy - Advanced Cancer, Stage IV Solid Tumor Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 46 | 2026-09-14 | 2026-10-15 |
| Psilocybin for Treatment of OCD-2 Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Francisco A Moreno | 20 | 2026-09-08 | 2026-05-12 |
Showing 20 of 138. Sign in to see all of them.
Depression (31) · Depressive Disorder, Major (25) · Depressive Disorder, Treatment-Resistant (20) · Alcoholism (17) · Stress Disorders, Post-Traumatic (12) · Anxiety Disorders (11) · Neoplasms (7) · Opioid-Related Disorders (7) · Anorexia Nervosa (5) · Depressive Disorder (5) · Bipolar Disorder (3) · Melanoma (3) · Mental Disorders (3) · Suicidal Ideation (3) · Agnosia (2)
Johns Hopkins University (10) · Centre for Addiction and Mental Health (6) · COMPASS Pathways (5) · NYU Langone Health (5) · University of Calgary (4) · M.D. Anderson Cancer Center (3) · Sheppard Pratt Health System (3) · University Health Network, Toronto (3) · University of Washington (3) · Washington University School of Medicine (3) · Anders Fink-Jensen, MD, DMSci (2) · Imperial College London (2) · Section for Affective Disorders; Northern Stockholm Psychiatry (2) · Sunstone Medical (2) · Unity Health Toronto (2)
United States (84) · Canada (27) · United Kingdom (6) · Denmark (4) · Ireland (3) · Sweden (3) · Belgium (2) · Czechia (2) · France (2) · Germany (2) · Switzerland (2) · Brazil (1) · Finland (1) · Israel (1) · Netherlands (1)
Frederick S Barrett, PhD (3) · Ishrat Husain, MBBS, MD (3) · Leah Mayo, PhD (3) · Michael Bogenschutz, MD (3) · Scott Aaronson, MD (3) · Alan K Davis, PhD (2) · Anders Fink-Jensen, Professor (2) · Anthony Back, MD (2) · Charles Raison, MD (2) · Moran Amit, MD (2) · Peggy C Nopoulos, MD (2) · Reginald Peters, MD (2) · Sandeep Nayak, MD (2) · Yvan Beaussant, MD (2) · Andrew M Novick, MD, PhD (1)
PMID 20819978, PMID 21674151, PMID 24550805, PMID 25586396, PMID 27578767, PMID 27909165, PMID 28704354, PMID 29577509, PMID 29764303, PMID 31543078, PMID 32371500, PMID 33146667, PMID 33852780, PMID 33902087, PMID 33993135, PMID 34744825, PMID 34867525, PMID 35001856, PMID 35411074, PMID 35431912, PMID 36001306, PMID 36044208, PMID 36241352, PMID 36322843, PMID 36332827, PMID 36532184, PMID 36636296, PMID 37142308, PMID 37276086, PMID 37337526, PMID 37488291, PMID 37651119, PMID 38055270, PMID 38105655, PMID 38247730, PMID 38279085, PMID 38326432, PMID 38359838, PMID 38483940, PMID 38605658, PMID 38956594, PMID 38988455, PMID 39260823, PMID 39343309, PMID 39695323, PMID 39741440, PMID 39741446, PMID 39764567, PMID 39823496, PMID 40018886
1DP2DA066200 (1), 1UG3DA062088-01 (1), 1UG3DA067126 (1), 2016 (1), 2017 (1), 2023 (1), 2025 (1), R01AA031417 (1), R01CA312541 (1), R03DA042336 (1), R25MH112473 (1), R34AT013077 (1), U01DA052174 (1)